



Targeted Cancer Therapy Using Monoclonal Antibodies

Guest Editor:

Prof. Dr. Vladka Čurin Šerbec
Blood Transfusion Centre of
Slovenia, Ljubljana, Slovenia

Deadline for manuscript
submissions:

closed (31 January 2023)

Message from the Guest Editor

Dear Colleagues,

Monoclonal antibodies (chimeric, humanized, and human) are also very successful in the treatment of autoimmune and dermatological diseases, among others. In the last decade, monoclonal antibodies, mainly human (isolated from patients or produced in transgenic mice), have also been developed to treat infectious diseases such as AIDS and COVID-19. Scientists have provided new technologies to prepare fully human antibodies, based on phage display—Prof. Sir Gregory Winter was awarded the Nobel prize in chemistry in 2018 for his pioneering work on this, for instance. We are still awaiting the first approved drug based on nanobodies (from camelid), and new doors have also opened for new targets for CAR-T therapy and for the preparation of monoclonal antibodies to these targets. All therapeutic monoclonal antibodies can be prepared as ADCs.

In this issue, we will cover the field of targeted cancer therapy using monoclonal antibodies as described above, and authors are encouraged and welcome to provide us with their topics of research (except pure clinical studies). Review articles are also welcome.

Prof. Dr. Vladka Čurin Šerbec
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. José L. Quiles

Department of Physiology,
Institute of Nutrition and Food
Technology “Jose Mataix”,
Biomedical Research Center,
University of Granada, Avda.
Conocimiento s/n, 18100 Armilla,
Granada, Spain

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI